Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25335686 | 0.72 | RAB9A (0.69) | NPSR1ALDH1A1RAB9ANPC1HSD17B10 | |
| SCHEMBL25337471 | 0.70 | ALDH1A1 (0.64) | ALDH1A1POLBRAB9ANPC1MAPT | |
| SCHEMBL25335779 | 0.69 | ALDH1A1 (0.75) | ALDH1A1L3MBTL1RAB9ANPC1MAPT | |
| SCHEMBL26047922 | 0.68 | NPSR1 (0.50) | NPSR1ALDH1A1POLBRAB9AMAPT | |
| SCHEMBL25335374 | 0.64 | ATM (0.77) | ALDH1A1L3MBTL1RAB9ANPC1MAPT | |
| SCHEMBL25334320 | 0.62 | ALDH1A1 (0.79) | NPSR1ALDH1A1POLBL3MBTL1RAB9A | |
| SCHEMBL25334790 | 0.62 | ALDH1A1 (0.67) | ALDH1A1RAB9ANPC1MAPTTSHR | |
| SCHEMBL25337696 | 0.62 | ALDH1A1 (0.79) | NPSR1ALDH1A1POLBL3MBTL1RAB9A | |
| SCHEMBL24549817 | 0.62 | ALDH1A1 (0.46) | NPSR1ALDH1A1L3MBTL1RAB9ANPC1 | |
| SCHEMBL24549745 | 0.62 | ALDH1A1 (0.46) | NPSR1ALDH1A1L3MBTL1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564547-B2 | Compositions, formulations, and methods for skin treatment | ODDITY LABS, LLC (US) | 2026-03-03 | — | — | US | disclosed |
| US-20230240960-A1 | COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT | ODDITY LABS, LLC | 2023-08-03 | — | — | US | disclosed |
| US-20230240960-A1 | COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT | ODDITY LABS, LLC | 2023-08-03 | — | — | US | disclosed |
| US-20230240960-A1 | COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT | ODDITY LABS, LLC | 2023-08-03 | — | — | US | disclosed |
| WO-2023133240-A1 | COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT | REVELA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230240960-A1 | COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT | CUTA, COL14A1, DSG1 | NPSR1 4619/4885ALDH1A1 3302/4885POLB 1183/4885 |
| US-12564547-B2 | Compositions, formulations, and methods for skin treatment | MCOLN1, H1-0, APOL1 | NPSR1 2810/4885ALDH1A1 1590/4885POLB 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.